News
![BMS_sign](https://pharmaphorum.com/wp-content/uploads/2020/05/BMS_sign.jpg)
BMS finally gets FDA OK for liso-cel, sets $410k launch pric...
Bristol-Myers Squibb finally has FDA approval for its CAR-T therapy liso-cel, which has been cleared by the US regulator as Breyanzi for certain forms of large B-cell lymphoma.